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Abstract: 
Background: Multiple Sclerosis is a neurodegenerative, autoimmune disease of the central 
nervous system. Both peripheral blood and central nervous system facets play a role in the 
pathophysiology. Extracellular vesicles are small membrane-bound vesicles that are released 
by most cells in response to stress, activation, or pathology. As extracellular vesicles can cross 
the blood-brain barrier, they have the ability to link peripheral blood inflammation to central 
nervous system pathology in Multiple Sclerosis. The aim of this study was to obtain a 
comprehensive picture of the cellular origins of plasma-borne extracellular particles in Multiple 
Sclerosis. 
Methods: Platelet-free plasma was obtained from 39 Multiple Sclerosis patients and 27 healthy 
controls via a series of centrifugation steps and assessed by flow cytometry. Plasma samples 
were stained with antibodies against CD4, CD8, CD14, CD20, CD41b, CD45, CD146, and 
CD235a. Gates were set using size-reference beads and extracellular particles were enumerated 
using commercial counting beads at known concentrations. 
Results: In relapsing patients (n=13) erythrocyte-derived (CD235a) extracellular particles were 
increased, while platelet-derived (CD41b), leukocyte-derived (CD45), and CD4+ T cell-
derived (CD4) extracellular particles were decreased compared to both healthy controls (n=27) 
(p<0.01) and secondary progressive Multiple Sclerosis patients (n=9) (p<0.05). Endothelium-
derived extracellular particles were increased in stable relapsing-remitting Multiple Sclerosis 
patients (n=17) compared to healthy controls (p<0.05). Extracellular particles from several 
different cells of origin correlated with each other and clinical parameters (e.g. disease 
duration, number of relapses, EDSS), though clinical correlations did not withstand corrections 
for multiple comparisons. 
Conclusions: Concentrations of erythrocyte-, leukocyte-, and platelet-derived extracellular 
particles were altered in relapsing Multiple Sclerosis patients and endothelium-derived 
extracellular particles were increased in stable relapsing-remitting patients compared to healthy 
controls. Extracellular particles may provide insights into altered crosstalk between peripheral 
blood cells in Multiple Sclerosis, which may lead to the discovery of novel therapeutic targets. 
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Abbreviations: 
adj.p  adjusted p-value 
AF  auto-fluorescence 
BBB  blood-brain barrier 
CD  cluster of differentiation 
CNS  central nervous system 
CSF  cerebrospinal fluid 
DMT  disease-modifying therapy 
EDSS  expanded disability status scale 
EP  extracellular particle 
EV  extracellular vesicle 
HC  healthy control 
IQR  interquartile range 
MISEV2018 minimal information for the studies of extracellular vesicles 2018 
MRI  magnetic resonance imaging 
MS  Multiple Sclerosis 
n/a  not applicable/not available/no answer 
PPMS  primary progressive Multiple Sclerosis 
RRMS  relapsing-remitting Multiple Sclerosis 
SD  standard deviation of the mean 
SNP  single nucleotide polymorphism 
SPMS  secondary progressive Multiple Sclerosis 
  
1. Introduction: 
Extracellular vesicles (EVs) are small membrane-bound vesicles. EVs are receiving increasing 
attention due to their involvement in intercellular communication (Abels and Breakefield, 
2016). Formerly considered cell debris, EVs are now known to be taken up by recipient cells 
and the cargo delivered to such recipient cells can be functional (Ridder et al., 2014). EVs are 
released in response to activation, stress, or pathology and their classification is based on 
biogenesis and size. Microvesicles, formed through outward budding of the plasma membrane, 
range from 100 nm to 1 µm. Exosomes are released upon fusion of multivesicular bodies with 
the plasma membrane and range from 30 nm to 150 nm (Abels and Breakefield, 2016). 
Distinguishing between EV subspecies is challenging, which has led to some confusion in the 
field. To circumvent this issue, both microvesicles and exosomes will be referred to as EVs. 
EVs can carry membrane proteins from their cell of origin on the outer membrane. Such 
proteins can be surveyed to determine the cellular origin of EVs in biological fluids 
(Zaborowski et al., 2015). 
EVs can be detected in biological fluids such as blood (Enjeti et al., 2016), urine (Pisitkun et 
al., 2004), cerebrospinal fluid (CSF) (An et al., 2013), and saliva (Iwai et al., 2017). In these 
fluids, EVs have provided an intriguing new source of potential biomarkers for many diseases, 
including Multiple Sclerosis (MS) (Saenz-Cuesta et al., 2014a). MS is a chronic inflammatory, 
autoimmune disease with a neurodegenerative component. Both the peripheral compartment 
and the central nervous system (CNS) are involved in MS (Dendrou et al., 2015). From a 
phenotypical standpoint, MS can be characterised as relapsing-remitting MS (RRMS), 
secondary progressive MS (SPMS), and primary progressive MS (PPMS) (Lublin et al., 2014). 
There are currently no blood-borne biomarkers specific to MS. Circulating EVs represent an 
attractive source of MS-specific biomarkers as they have the ability to cross the blood-brain 
barrier (BBB) (Matsumoto et al., 2017a; Matsumoto et al., 2017b); thus, they may link 
peripheral inflammation to CNS pathology. Additionally, EVs from the CNS may transverse 
the BBB and access the peripheral circulation, where they have been detected (García-Romero 
et al., 2017) and from where they may contribute to systemic inflammation (Dickens et al., 
2017). 
In MS, several circulating EVs have been assessed using flow cytometry. During relapse, an 
increase in plasma endothelial EVs (CD31+ and CD51+) has been observed (Marcos-Ramiro et 
al., 2014; Minagar et al., 2001). The increase in endothelial-derived EVs was also detected in 
other clinical forms of MS including RRMS, SPMS, and clinically isolated syndrome (Marcos-
Ramiro et al., 2014). Some endothelial EVs (CD51+) remained elevated in remission, possibly 
indicating chronic BBB damage (Minagar et al., 2001). Endothelial EVs were found to form 
complexes with leukocytes and these complexes correlated positively with gadolinium-
enhancing lesions identified using magnetic resonance imaging (MRI). Endothelial EVs 
appeared to preferentially bind and activate monocytes over lymphocytes and neutrophils in 
vitro (Jy et al., 2004). Activated monocytes were found to facilitate transendothelial migration, 
a crucial step in MS pathology (Jy et al., 2004).  
Similar to endothelium-derived EVs, platelet-derived EVs were found to be increased in MS 
patients compared to healthy controls (HCs) (Marcos-Ramiro et al., 2014; Saenz-Cuesta et al., 
2014a), while B cell-derived EVs (CD19+) were decreased (Zinger et al., 2016). Collectively, 
circulating EVs from MS patients were found to cause greater disruption of endothelial barriers 
than circulating EVs from HCs at equal concentrations, highlighting their potential 
involvement in MS pathology (Marcos-Ramiro et al., 2014). Differences in circulating EVs 
were also observed between MS phenotypes, with greatest increases in platelet-, leukocyte-, 
and monocyte-derived EVs observed in RRMS, while SPMS patients had levels resembling 
those of HCs (Saenz-Cuesta et al., 2014a). These observations support the hypothesis that MS 
is more confined to the CNS in progressive disease (Dendrou et al., 2015). Disease-modifying 
therapies (DMTs) have been found to alter the levels of circulating EVs. Interferon 1β 
(Sheremata et al., 2006) and fingolimod (Zinger et al., 2016) brought about a decrease in 
circulating endothelium-derived EVs. 
A comprehensive study of plasma-borne EVs may provide insights into the involvement of 
peripheral blood cells in MS pathology and indicate sources of novel biomarkers. The aim of 
this study was to undertake a comprehensive survey of circulating extracellular particles (EPs) 
in MS patients and HCs, and to identify potential links to disease activity and disability. 
2. Methods: 
2.1. Ethics statement: 
Ethical approval for this study was obtained from the University of Newcastle (H-505-0607) 
and the Hunter New England Health Ethics Committee (2019/ETH12346). Participants were 
recruited through the MS clinic at the John Hunter Hospital and the Hunter Medical Research 
Institute. All participants gave written informed consent. 
2.2. Cohort: 
Inclusion criteria were: MS patients had to 1) be ≥ 18 years old, 2) meet 2017 McDonald criteria 
for MS (Thompson et al., 2018), 3) be treatment-naïve or off DMT for > 6 months prior to 
sample collection (exceptions were made for relapse samples) and 4) not have received 
corticosteroids in the 90 days prior to sample collection (exceptions were made for relapse 
samples). Patients were excluded if they had an autoimmune condition other than MS. HCs 
were age- (± two years) and gender-matched and could not suffer from any autoimmune or 
CNS disease. Exclusion criteria were participants who were pregnant or breastfeeding. 
Additional patient information was obtained through MSBase (Butzkueven et al., 2006) and 
HCs completed a questionnaire. Physical activity levels of patients and HCs were self-reported 
and based on the Exercise and Sport Science Australia Intensity Guidelines (Norton et al., 
2010). Patients were considered stable, “RRMS” from here on, if they had not presented with 
any new clinical symptoms or gadolinium-enhancing lesions on MRI in the 120 days pre-
collection and 90 days post-collection. Active relapse, “Relapse” from here on, was defined as 
new MS-related symptoms or evidence of gadolinium-enhancing lesions on MRI within a 
month of sample collection. Information regarding infectious diseases was not recorded at the 
time of sample collection. 
The cohort consisted of 17 RRMS patients, 13 Relapse patients, 9 SPMS patients, and 27 HCs. 
Six of the relapsing patients (46.2%) received corticosteroids in the three months prior to 
sample collection. All participants were female and all collected blood samples were non-
fasting blood samples. 
2.3. Blood processing: 
Nine mL of blood were collected into lithium-heparin coated vacutainers (Vacuette, Greiner 
Bio-One, Austria). All blood samples were processed within six hours of collection and 83% 
of samples were processed within four hours of collection. Platelet-free plasma was obtained 
via centrifugation (1500 x g for 15 min at room temperature with break off, 2500 x g for 10 
min at room temperature with break on, 4500 x g for 15 min at 4°C with break on). Platelet-
free plasma was stored at -80°C until samples were stained for flow cytometry. Haemolysis 
was checked visually using a colour scale when samples were thawed. This enrichment method 
falls into the category of “high recovery, low specificity” according to the Minimal Information 
for Studies of Extracellular Vesicles 2018 (MISEV2018) guidelines (Thery et al., 2018). Due 
to the enrichment method’s lack of specificity, plasma-borne particles of this study are termed 
extracellular particles (EPs), not EVs. 
2.4. SDS-PAGE and western blotting: 
Platelet-free plasma samples were diluted 1:20 with phosphate-buffered saline, mixed with 
sample loading buffer (Tris-HCl, glycerol, 2% SDS, bromophenol blue, β-mercaptoethanol) 
and boiled at 95°C for five minutes prior to being size separated by elcetrophoresis on a 10% 
polyacrylamide gel (150 V, 60-70 min). Size separated proteins were transferred to a 
nitrocellulose membrane (100 V, 60 min), which was blocked with Odyssey blocking buffer 
(LICOR Biosciences, USA), and incubated with primary antibodies overnight. The following 
primary antibodies were used: mouse anti-ApoA1 (1:1000), mouse anti-CD63 (1:1000), mouse 
anti-Alix (1:1000), and rabbit anti-albumin (1:750). All primary antibodies were purchased 
from Thermo Fisher Scientific (USA). Secondary IRDye-conjugated antibodies (goat anti-
rabbit and donkey-anti-mouse, 1:25,000) were purchased from LICOR Biosciences (USA) and 
added to the membranes for one hour. Membranes were scanned on a LICOR Odyssey scanner 
(LICOR Biosciences, USA). 
2.5. Total protein assay: 
Total protein concentrations were determined with the Qubit protein assay kit (Invitrogen, 
USA) as per manufacturer instructions. Plasma samples were diluted 1:39 with Milli Q water 
for the protein assay. 
2.6. Flow cytometry:  
Ten µl platelet-free plasma was stained with fluorescently labelled antibodies against CD235a 
(APC, Clone GA-R2), CD41b (FITC, Clone HIP2), CD45 (FITC, Clone 2D1), CD146 (PE, 
Clone P1H12), CD20 (APC, Clone 2H), CD4 (FITC, Clone OKT4), CD8a (FITC, Clone RPA-
T8), and CD14 (APC, Clone RPA-T8). Antibodies were purchased from BD Pharmingen, USA 
(CD235a, CD41b, CD20, CD14), Invitrogen, USA (CD146), and StemCell, Canada (CD45, 
CD4, CD8). Table 1 shows cells typically expressing the used CD markers. 
  






















































































CD4 L3T4, W3/25, T4, Leu3a + -  - - + + - - - 
CD8a Leu2, T8, Lyt2,3 + -  + - - - - - - 
CD14 LPS-receptor - -  -  + +    
CD20 B1, Bp35 + + - - - - - - - - 
CD41b 
GPIIb, integrin αIIb, 
platelet membrane 
glycoprotein IIb, 
ITGA2B, integrin α2b, 
human platelet antigen 3 
- - - - + - - + - - 
CD45 
Leukocyte common 
antigen, T200, B220, Ly5, 
PTRPC 
+ + + + + + + - - - 
CD146 
Muc-18, S-endo, MCAM, 
Mel-CAM 




sialoglycoprotein A, MN 
blood group antigen, 
PAS-2 
- - - - + - -  +  
Highlighted cells indicate for which cell(s) the CD markers were used for in this study. This 
table was adapted from bdbiosciences.com/cdmarkers. CD – cluster of differentiation. 
 
Samples were run on a modified LSRFortessa (BD Biosciences, USA) with a 0.1 µm sheath 
fluid filter. Staining buffer was filtered with 0.1 µm filters. Size gates were set using flow 
cytometer calibration and size reference beads (Invitrogen, USA). An EP gate was set for 
events that were ˂  1 µm. With synthetic size reference beads observing different light scattering 
than biological EPs, size gates are only an approximation of the EPs’ size. Plasma EPs were 
quantified using CountBright beads (Invitrogen, USA). Negative controls (staining buffer and 
antibodies only, no sample) were run with every batch of samples. Samples were highly diluted 
(dilution factor = 40) and run at low flow rate to mitigate coincidence. Plasma EP 
concentrations were calculated as follows: 
 
𝑝𝑙𝑎𝑠𝑚𝑎 𝐸𝑃𝑠 (𝑝𝑒𝑟 µ𝑙) =  (((
#𝐸𝑃𝑠
#𝑏𝑒𝑎𝑑𝑠
 ∗  𝑏) ∗  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ) − 𝑎) ∗  (1 − 𝐴𝐹) 
𝑏(𝑏𝑒𝑎𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒) =
𝑏𝑒𝑎𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛  ∗  𝑏𝑒𝑎𝑑 𝑣𝑜𝑙𝑢𝑚𝑒
𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒
  
𝑎(𝐸𝑃𝑠 𝑖𝑛 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙) = (
#𝐸𝑃𝑠
#𝑏𝑒𝑎𝑑𝑠
 ∗  𝑏) ∗  𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
𝐴𝐹  −   𝑎𝑢𝑡𝑜𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒  
With the BD LSR Fortessa with photomultiplier tube upgrade being able to differentiate 
particles of > 200 nm from background noise, EPs surveyed by flow cytometry were large EPs 
(Thery et al., 2018). 
2.7. Statistics: 
Statistical analysis was performed in R (v. 3.6.1). Distribution of the data was checked visually, 
(box plots and histograms), and through kurtosis and skewness measures. The data followed a 
non-parametric distribution. Therefore, EP data is reported as median and interquartile range 
(IQR). Differences between groups were determined using Wilcoxon signed-rank test. 
Significance threshold was set at p < 0.05. Correlations between EPs were determined through 
Pearson’s correlation coefficients and correlations between EPs and clinical parameters were 
determined through Spearman’s rho. P-values were adjusted for multiple comparisons using 
the Benjamini-Hochberg approach. 
  
3. Results:  
Participant demographics are summarised in Table 2. Of the relapsing patients, four patients 
were on DMT at the time of sample collection (1 x fingolimod, 1 x glatiramer acetate, 2 x 
interferon). Additional participant and sample information is summarised in Supplementary 
File S1. 














*HC were split into HC (RRMS) and HC (SPMS) to highlight age-matching of the HCs to 
RRMS and SPMS patients. As no correlations were identified between EPs and age in the HC 
group (see 3.4 Suggestive correlations between circulating EPs and clinical parameters), we 
decided not to split the controls for subsequent analyses. Data is shown as mean (± SD). EDSS 
– expanded disability status scale; HC – healthy control; RRMS – relapsing-remitting Multiple 
Sclerosis; SD – standard deviation of the mean; SPMS – secondary progressive Multiple 
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  n/a n/a 
13.0 
(±17.4) 














Number of relapses   4 (±5) 4 (±3) 5 (±4) 
Steroids in the last 3 
months (% yes) 
  46.2 0 0 







3.1. EP Characteristics: 
All samples showed minimal signs of haemolysis (˂20 mg/dL haemoglobin). Samples 
contained evidence of EV markers CD63 (EV transmembrane protein) and Alix (EV cytosolic 
protein) (Thery et al., 2018), but also of contaminants typically found in plasma (albumin and 
lipoproteins, indicated through presence of ApoA1) (Fig. 1). Together with the low total 
particle:protein ratios (Supplementary Table S2), this indicates an enrichment protocol of “high 
recovery [and] low specificity” (Thery et al., 2018), thus surveyed particles have been termed 
EPs. 
With the modified LSR Fortessa’s size detection limit lying around 200 nm, EPs surveyed as 
part of this study were large EPs (200-1000 nm). Flow cytometry gating strategies are shown 
in Figure 2. Around 10% of all extracellular particles stained for selected CD markers across 
all four groups (, Table 3, Supplementary Figure S2). Total EP numbers varied from 2,430,248 
(IQR: 3,415,552) in relapse patients (n = 13) to 3,440,895 (IQR: 41,543,052) in SPMS patients 
(Table 3). There were no correlations between EP numbers and bench time (Supplementary 
Table S3). 
  
Table 3: Percent (%) extracellular particles stained for selected cluster of differentiation 
markers. 
 HCs 
(n = 27) 
Relapse 
(n = 13) 
RRMS 
(n = 17) 
SPMS 













1.29 5.19 3.20 1.96 
CD41b EPs 
(%) 
3.98 1.29 2.71 5.72 
CD146 EPs 
(%) 
0.85 2.34 1.45 1.12 
CD45 EPs 
(%) 
0.79 0.47 0.69 1.02 
CD4 EPs  
(%) 
1.53 0.09 1.87 0.70 
CD20 EP 
(%)s 
0.20 0.24 0.28 0.21 
CD8 EPs 
(%) 
0.27 0.21 0.22 0.09 
CD14 EPs 
(%) 
0.10 0.20 0.16 0.15 
All stained EPs 
(%) 
9.01 10.04 10.58 10.97 
EPs of 200-1000 nm diameter are reported. EP – extracellular particle; HC – healthy control; 
IQR – interquartile range; RRMS-relapsing-remitting Multiple Sclerosis; SPMS – secondary 
progressive Multiple Sclerosis. 
  
3.2. Differences in circulating EP numbers between MS disease courses and HCs: 
The levels of circulating EPs of different cellular origins varied between MS patients and HCs, 
as well as between MS patients of different disease courses. In HCs, platelet-derived EPs were 
the most prevalent, followed by erythrocyte-, leukocyte-, and endothelium-derived EPs 
respectively. In relapse patients, erythrocyte-derived EPs were most prevalent, followed by 
endothelium-, platelet-, and leukocyte-derived EPs. In RRMS patients, erythrocyte-derived 
EPs were the most prevalent plasma EPs, followed by platelet-, endothelium-, and leukocyte-
derived EPs. In SPMS patients, platelet-derived EPs were the most prevalent plasma EPs, 
followed by erythrocyte-, endothelium-, and leukocyte-derived EPs ( Fig. 4, Supplementary 
Table S4). 
Erythrocyte-derived EPs (CD235a): Erythrocyte-derived EPs were more abundant in relapse 
patients compared to HCs (p < 0.001) and SPMS patients (p < 0.05). There was a trend towards 
increased erythrocyte-derived EPs in stable RRMS patients compared to HCs, though this was 
not statistically significant. 
Platelet-derived EPs (CD41b): Platelet-derived EPs were decreased in relapse patients 
compared to HCs (p < 0.01) and SPMS patients (p < 0.05). No further differences in platelet-
derived EPs were observed. 
Endothelium-derived EPs (CD146): Endothelium-derived EPs were increased in RRMS 
patients compared to HCs (p < 0.05). No other differences in endothelium-derived EPs were 
observed. 
Leukocyte-derived EPs (CD45): Leukocyte-derived EPs were decreased in relapse patients 
compared to HCs (p < 0.05) and SPMS patients (p < 0.05). No further differences in leukocyte-
derived EPs were observed. Leukocyte-derived EPs can be further divided into immune cell 
subsets. To look at these subsets in more detail, CD4+ T cell-, CD8+ T cell-, B cell-, and 
monocyte-derived EP numbers were assessed. 
CD4+ T cell-derived EPs: Relapse patients’ CD4+ T cell-derived EPs were decreased compared 
to HC CD4+ T cell-derived EPs (p < 0.001), RRMS patient CD4+ T cell-derived EPs (p < 0.001), 
and SPMS patient CD4+ T cell-derived EPs (p < 0.05). 
There were no significant differences in EPs from any other immune cell subsets. 
3.3.EPs from different cells of origin correlated with each other: 
The numbers of several plasma-borne EPs showed moderate (0.7 > r > 0.5) to strong (r ≥ 0.7) 
correlation with each other (Table 4). 
In all samples combined (HCs and MS, n = 66), leukocyte-derived EPs positively correlated 
with both CD8+ T cell-derived EPs (r = 0.636; adj.p = 1.74E-06) and platelet-derived EPs (r = 
0.488; adj.p = 0.004); B cell-derived EPs positively correlated with monocyte-derived EPs (r 
= 0.595; adj.p = 2.50E-05); and erythrocyte-derived EPs positively correlated with endothelial 
cell-derived EPs (r = 0.596; adj.p = 1.79E-05). 
In HC samples (n = 27), platelet-derived EPs positively correlated with endothelium-derived 
EPs (r = 0.716; adj.p = 0.003). 
In SPMS patient samples (n = 9), leukocyte-derived EPs positively correlated with CD8+ T 
cell-derived EPs (r = 0.952; adj.p = 0.010). 
The best correlations between EP subtypes were observed in relapse patients (n = 13), where 
CD4+ T cell-derived EPs positively correlated with CD8+ T cell-derived EPs (r = 0.951; adj.p 
= 8.25E-05), platelet-derived EPs (r = 0.961; adj.p = 2.37E-05), and leukocyte-derived EPs (r 
= 0.956; adj.p = 4.68E-05). Additionally, CD8+ T cell-derived EPs positively correlated with 
platelet-derived EPs (r = 0.966; adj.p = 1.23E-05) and leukocyte-derived EPs (r = 0.950 adj.p 
= 8.62E-05). Leukocyte-derived EPs positively with platelet-derived EPs (r = 0.986 adj.p = 
8.33E-05). 
No correlations between circulating EPs were identified in RRMS patients. 
  
Table 4: Pearson’s correlation coefficients between extracellular particle subtypes. 
EPs 
All samples 
(n = 66) 
HC 
(n = 27) 
Relapse 
(n = 13) 
SPMS 
(n = 9) 
CD4 & CD8   
0.951 
(p = 8.25E-05) 
 
CD4 & CD41b   
0.961 
(p = 2.37E-05) 
 
CD4 & CD45   
0.956 
(p = 4.68E-05) 
 
CD8 & CD41b   
0.966 
(p = 1.23E-05) 
 
CD8 & CD45 
0.636 9 
(p = 1.74E-06) 
 0.950 
(p = 8.62E-05) 
0.952 
(p = 0.010) 
CD14 & CD20 
0.594 
(p = 2.50E-05) 
   
CD41b & CD45 
0.488 
(p = 0.004) 
 0.986 
(p = 8.33E-05) 
 
CD41b & CD146  
0.716 
(p = 0.003) 
  
CD146 & CD235a 
0.596 
(p = 1.79E-05) 
   
p-values have been adjusted for multiple comparisons. EP – extracellular particle; HC – healthy 
control; SPMS – secondary progressive Multiple Sclerosis. 
  
3.4. Suggestive correlations between circulating EPs and clinical parameters: 
Circulating EP levels also showed suggestive correlations with a range of clinical parameters. 
These correlations showed trends in the direction of increase/decrease that were statistically 
significant prior to multiple comparison corrections but did not withstand this statistical 
correction (Table 5). Adjusted p-values nearing significance are highlighted throughout the 
following paragraphs. 
In all MS patients, CD8+ T cell-derived EPs decreased with longer disease duration and 
increased with later age of onset. Both platelet- (adjusted p-value = 0.136) and leukocyte-
derived EPs increased with time since last relapse; matching the trend of decreased platelet- 
and leukocyte-derived EPs in relapsing patients compared to SPMS patients (Fig. 3). 
In RRMS patients, CD4+ T cell-derived EPs decreased as time since patients’ last relapse 
increased. B cell-derived EPs increased with increasing disability measured by expanded 
disability status scale (EDSS) scores and endothelium-derived EPs increased with increasing 
relapses since onset of the disease. 
In SPMS patients, both CD8+ T cell-derived EPs and endothelium-derived EPs decreased with 
increasing disease duration, while B cell-derived EPs increased with increasing progression 
duration (adjusted p-value = 0.055). The more relapses SPMS patients had experienced 
throughout their disease, the lower their number of circulating monocyte-derived EPs; and the 
more physically active the patient, the lower their B cell-derived EPs. Platelet-derived EPs 
decreased with age in SPMS patients and leukocyte-derived EPs were more numerous in 
patients with older ages of onset (adjusted p-value = 0.157), while decreasing with increasing 
time since patients’ last relapse. 
In relapse patients, CD8+ T cell-derived EPs were found to positively correlate with patients’ 
body mass index and platelet-derived EPs negatively correlated with patients’ EDSS scores. 
Correlations between EP numbers and clinical parameters (age, body mass index, physical 
activity level, disease duration, age at onset, time since last relapse, number of relapses since 
disease onset, progression duration and EDSS score) were checked for all groups (HCs, 
Relapse, RRMS and SPMS) as applicable. All correlations that were statistically significant 
prior to corrections for multiple comparisons are shown in Table 5. 
Table 5: Correlations (Spearman’s rho) between plasma extracellular particles and 
clinical parameters. 
EP Clinical parameter 
MS 
rho p–value (p.adj) 
CD8 
Disease duration -0.345 0.003 (0.222) 
Age at onset 0.472 0.003 (0.222) 
CD41b 
Time since last relapse 
0.481 0.002 (0.136) 
CD45 0.37 0.02 (0.994) 
 Relapse 
rho p-value (p.adj) 
CD8 Body mass index 0.833 0.01 (0.641) 
CD41b EDSS score -0.749 0.008 (0.512) 
  RRMS 
  rho p-value (p.adj) 
CD4 Time since last relapse -0.627 0.007 (0.442) 
CD20 EDSS score 0.514 0.041 (0.924) 
CD146 
Number of relapses since 
onset 
0.561 0.019 (0.925) 
  SPMS 
  rho p-value (p.adj) 
CD8 Disease duration -0.717 0.03  (0.983) 
CD14 
Number of relapses since 
onset 
-0.681 0.044 (0.983) 
CD20 Progression duration 0.929 0.001 (0.055) 
 Physical activity -0.729 0.040 (0.983) 
CD41b Age -0.733 0.025 (0.982) 
CD45 Time since last relapse -0.677 0.05 (0.983) 
 Age at onset 0.867 0.002 (0.157) 
CD146 Disease duration -0.667 0.05 (0.983) 
EDSS – expanded disability status scale; EP – extracellular particle; MS – Multiple Sclerosis; 
p.adj – adjusted p-value; RRMS – relapsing-remitting Multiple Sclerosis; SPMS – secondary 
progressive Multiple Sclerosis. 
  
4. Discussion: 
Altered levels of immune cell-derived EPs (CD45 and CD4) were detected, but differences in 
erythrocyte-derived (CD235a), endothelium-derived (CD146), and platelet-derived (CD41b) 
EPs were also evident. Many of the EP subtypes correlated both with each other and 
suggestively correlated with clinical measures in MS. While the enrichment protocol did not 
exclusively isolate EVs, differences in EPs highlighted by this study may still provide insights 
into potential EV sources and disease biomarkers. 
MS is assumed to be an autoimmune disease that relies on both dysfunctional T and B cells; 
thus, it may be hypothesised that these cells contribute to altered EV pools in MS patient 
plasma. Interestingly, both leukocyte-derived EPs and CD4+ T cell-derived EPs were decreased 
in relapse patients compared to HCs and SPMS patients (Fig. 4). 
The decrease of CD4+ T-cell derived EPs in relapse patients may at first seem to contradict the 
theory that MS is largely driven by autoreactive CD4+ T cells (Dendrou et al., 2015). EV 
secretion increases in rapidly proliferating cells that are activated by the immune system 
(Selmaj et al., 2017) and under many pathological circumstances (Abels and Breakefield, 
2016). So, an increase in CD4+ T cell-derived EPs may be expected. However, a study by Jelcic 
et al. (Jelcic et al., 2018) indicated that while auto-proliferation of CD4+ T cells is elevated in 
MS patients during remission, it significantly decreases during relapse. This supports the 
finding of reduced circulating CD4+ T cell-derived EPs in relapse patients. These observations 
might reflect migration of pathogenic CD4+ T cells into the CNS during relapse (Dendrou et 
al., 2015; Jelcic et al., 2018). 
The decrease in CD45+ EPs in relapse patients may be similarly explained. CD45 is found on 
all differentiated haematopoietic cells with the exception of erythrocytes, platelets, and plasma 
cells (Hermiston et al., 2003). In this study, CD45 was exploited to enumerate EPs originating 
from all leukocytes. CD45 has been previously linked to MS, where a single nucleotide 
polymorphism (SNP), 77C → G, appeared to be overrepresented in MS patients. Individuals 
who carried this SNP had stronger expressions of the high molecular weight isoforms of CD45 
(CD45RA, CD45RB, CD45RC), but decreased expression of full-length CD45 (CD45ABC) 
and CD45RO. Expression of high molecular weight isoforms of CD45 has been linked to 
prolonged immune cell activation, which may be contributing to the inflammation observed in 
MS patients leading up to a relapse (Jelcic et al., 2018; Vyshkina et al., 2004). The CD45 
antibody used in this study (FITC, Clone 2D1, StemCell, Canada), can detect all CD45 
isoforms. Thus, a decrease in CD45+ EPs in relapse patients may reflect the migration of 
activated inflammatory cells out of the blood compartment into the CNS during relapse. This 
hypothesis is also supported by the suggested increase in CD45+ EPs in MS patients following 
a relapse (Table 5). Concurrently, a suggestive negative correlation was observed between 
CD45+ EPs and time since relapse in SPMS patients (Table 5). This correlation may support 
the reduced peripheral involvement in later, more progressive stages of the disease (Dendrou 
et al., 2015). 
One of the limitations of this study is that information regarding infectious diseases was not 
recorded at the time of sample collection. Hence, differences in CD45+ and CD4+ immune cell-
derived EPs may be driven by an inflammatory response to infection and not active relapse. 
Nonetheless, the significant decrease in CD45+ and CD4+ EPs in relapse patients only, supports 
that differences in these EP numbers are driven by MS-related disease activity in these patients 
rather than infection. Future studies should aim to record information on infectious diseases to 
further investigate this hypothesis. 
Like CD4+ and CD45+ EPs, platelet-derived EPs also appeared to be decreased in relapse 
patients compared to both SPMS patients and HCs. In MS, activated platelets may bind to 
leukocytes and endothelial cells of the BBB, as evidenced by ex vivo studies (Dziedzic and 
Bijak, 2019). P selectin on platelet-derived EVs has been observed to bind to its ligands P-
selectin glycoprotein ligand 1 and platelet-endothelial cell adhesion molecule-1 on 
lymphocytes. This binding up-regulated the expression of α4β1 integrins, facilitating 
lymphocyte tethering to the BBB (Saenz-Cuesta et al., 2014b; Sheremata et al., 2008). A 
decrease in platelet-derived EPs during relapse may reflect the timing of sample collection. 
Relapse samples were collected after patients presented with new neurological symptoms or 
gadolinium-enhancing lesions on MRI, so arguably after lymphocytes gained access to the 
CNS through a damaged BBB (Dendrou et al., 2015; Jelcic et al., 2018). Thus, platelets and 
platelet-derived EPs involved in the breach of BBB integrity and lymphocyte infiltration may 
no longer be detectable in the circulation at this point. A possible increase in platelet-derived 
EPs was observed after relapse, as evidenced by the suggestive correlation between CD41b+ 
EPs and time since relapse (Table 5). Previous studies reported an increase in CD61+ platelet-
derived EVs in RRMS patients during remission (Saenz-Cuesta et al., 2014a; Sheremata et al., 
2008). While a similar trend can be observed in RRMS patients recruited for this study, it is 
not statistically significant and the use of different clusters of differentiation (CDs) and small 
sample size may account for these discrepancies. As seen in Table 1, the same CD molecule is 
expressed on more than one cell population and similarly more than one CD molecule may be 
characteristic of a given cell, making it difficult to sensitively and specifically characterise the 
cellular origin of EPs and EVs based on a single CD marker (Clark et al., 2016). Typically, 
cells are characterised based on the presence and absence of multiple CDs and failure to 
characterise the cellular origin of EPs using a multitude of CD markers is one of the limitations 
of this study. 
Endothelium-derived EPs were increased in RRMS patients and are likely reflecting the 
activated and damaged endothelium, which enables lymphocytic infiltration (Dendrou et al., 
2015). They also suggestively correlated with the total number of relapses RRMS patients 
suffered (Table 5), possibly reflecting increased chronic BBB damage in these patients. Other 
studies have also found endothelium-derived EVs to reflect chronic BBB damage (Saenz-
Cuesta et al., 2014b). 
Interestingly, erythrocyte-derived EPs were increased during relapse. Erythrocytes may be 
involved in MS by contributing to oxidative stress in the periphery and BBB damage through 
altered phenotypes (Groen et al., 2016). Erythrocyte-derived EVs are known to be 
inflammatory (Danesh et al., 2014) and may also be involved in BBB damage (Mantel et al., 
2016), but have not yet been investigated in MS. In Parkinson’s disease, erythrocyte-derived 
EVs were found to cross the BBB and carry α-synuclein into the CNS, contributing to its 
pathogenic accumulation (Matsumoto et al., 2017b). In MS, erythrocyte-derived EVs may be 
involved in inflammation, BBB disruption, or communication between the blood compartment 
and the CNS, but further research is needed to investigate all three hypotheses. 
Several of the EP subtypes correlated with each other (Table 4), possibly indicating coordinated 
activation of their cells of origin, especially during relapse. As EPs are typically released in 
response to cellular activation, proliferation, or pathology (Selmaj et al., 2017), further 
investigation of this coordinated EP release may provide additional insights into the crosstalk 
between different cells in MS. While correlations between EPs of different cells may raise 
questions around their distinction, this study only looked at one EP surface marker. EP cargo 
and functions may prove more variable. It is hypothesised that correlations between EPs merely 
indicate simultaneous activation or stress of their cells of origin and not necessarily that the 
EPs are the same. For instance, erythrocyte- and platelet-derived EPs may be contributing to 
BBB damage (Jy et al., 2004; Mantel et al., 2016), whereas an increase in endothelial-derived 
EPs may simply be a result of this damage (Saenz-Cuesta et al., 2014b). 
While moderate correlations were identified between CD14 & CD20 positive EPs and CD146 
& CD235a positive EPs in all samples combined, these correlations were not identified in the 
subgroup analysis (Table 4). This may be a reflection of the small sample size as trends toward 
these correlations were identified in the subgroups, though these did not reach significance 
(data not shown). 
Further, only around 10% of all EPs stained positive for the selected CD markers (Table 3). 
The remaining EPs may include protein aggregates, lipoproteins, and EPs from other cells of 
origin. However, as previously noted (Alberro et al., 2019), EPs only harbouring a few CD 
markers may not be counted as positive for a given CD molecule. It also appears that not every 
cell surface marker ends up on the cell’s EPs. CD45 is expressed on all leukocytes with the 
exception of plasma cells (Vyshkina et al., 2004), yet CD45+ EPs were not always more 
numerous than CD4+, CD8+, and CD20+ EPs combined. Consequently, circulating EP numbers 
from investigated cells of origin may be greater than reported. 
There were several suggestive correlations between circulating EPs and clinical measures; 
however, following correction for multiple comparisons, none of the correlations remained 
statistically significant. This may be due to the small sample size of this underpowered study, 
particularly when considering the correlation between B cell-derived EPs and progression 
duration in SPMS patients, which remained nearly statistically significant (adjusted p-value = 
0.055) (Table 5). B cells have been previously linked to progressive MS (Romme Christensen 
et al., 2013). Therefore, B cell-derived EPs may relate information from peripheral B cells to 
the CNS to contribute to the disease. Evidence of B cell-derived EPs in SPMS patients’ CSF 
would support this hypothesis and should be assessed by future studies. EP numbers did not 
correlate with bench time, indicating that the prolonged bench time (4-6 h) of 11 samples 
(approx. 17% of samples) did not affect the results of this study. 
While some studies have looked at EV surface markers as a potential source of biomarkers 
(Saenz-Cuesta et al., 2014b), this study has found EP surface markers to be non-specific. Age 
and body mass index (Table 5) may be affecting circulating EP levels, which has also been 
highlighted by other studies (Enjeti et al., 2017). This lack of specificity indicates that EP 
surface markers may not be suitable as biomarkers. Nonetheless, there may be merit in 
investigating the cargo of EVs for such purposes. 
5. Conclusions 
In conclusion, the numbers of several circulating EPs are altered during relapse, indicating 
altered intercellular communication in the peripheral blood compartment during disease 
activity. Differences in circulating EP levels are not all specific to disease or disease subtype 
and some alterations may be driven by other factors, such as age and body mass index. 
However, further research into circulating EPs (and EVs) in larger cohorts, so that adjustments 
for confounding factors can be made, and using an expanded panel of markers may provide 
clues into their role in MS pathogenesis. An improved understanding of EV communication in 
MS could lead to the discovery of targets for new therapies and an improved understanding of 
disease pathology, especially regarding the communication between the peripheral blood 




Figure 1: Sample characteristics. Sample western blots of platelet-free plasma looking at 
Alix, albumin, CD63 and ApoA1 in one sample of median EP number in each group (HC, 
RRMS, SPMS, Relapse). Full western blots are shown in Supplementary Figure S1. EP: 
extracellular particle; HC – healthy control; RRMS – relapsing-remitting Multiple Sclerosis; 
SPMS – secondary progressive Multiple Sclerosis. 
 
Figure 2: Gating strategies for extracellular particle flow cytometry. A: Size reference 
beads (1 µm and 2µm) run for 30 seconds on high flow rate. B: CountBright beads (red in 
circle) run for 30 sec on high flow rate. Only CountBright beads that fell into the circular gate 
on the forward-scatter/side-scatter plot and stained positive for FITC (C gate) were counted. 
C: Filtered staining buffer run for 30 sec on high flow rate. D: Platelet-free plasma sample run 
on low flow rate until 1500 CountBright beads were obtained. E: The same platelet-free plasma 
as panel D, gated for CD146 (PE) and CD45 (FITC) positive events. 
 
Figure 3: Tukey boxplots of plasma-borne extracellular particles. Concentrations of 
plasma-borne erythrocyte- (CD235a), platelet- (CD41b), endothelium- (CD146), leukocyte- 
(CD45), as well as CD4+ T cell- (CD4), CD8+ T cell- (CD8), B cell- (CD20), and monocyte-
derived (CD14) EPs are shown by subject group (HC: n = 27, blue; Relapse: n = 13, orange; 
RRMS (stable): n = 17, light green; SPMS: n = 9, dark green). White circles represent outliers 
defined as deviating more than 1.5-fold from the upper/lower quartile. EP – extracellular 
particle; HC – healthy control; RRMS – relapsing-remitting Multiple Sclerosis; SPMS – 
secondary progressive Multiple Sclerosis; *** - p < 0.001; ** - p < 0.01; * - p < 0.05. 
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Supplementary File S1: Additional participant and sample information. 
Supplementary Table S1: Additional participant and sample information. 
 HC Relapse RRMS SPMS 
n 27 13 17 9 
BMI 
(kg/m2) 
Mean (SD) 27.8 (6.3) 24.4 (5.2) 27.5 (7.1) 30.1 (3.6) 
missing 
data (n) 




Sedentary 60.0 4.0 16.7 62.5 
Light 20.0 28.0 50.0 25 
Moderate 0.0 52.0 8.3 12.5 
Vigorous 20.0 16.0 8.3 0 
High 0.0 0.0 0.0 0 
missing 
data (n) 
8 2 5 1 
Time of 
Collection 
% AM 75.0 74.1 64.7 77.8 
* Physical activity levels are based on the Exercise and Sport Science Australia intensity 
guidelines. BMI – body mass index; HC – healthy control; RRMS – relapsing-remitting 
Multiple Sclerosis; SD – standard deviation of the mean SPMS – secondary progressive 
Multiple Sclerosis. 
Information on menopause, time of last exercise, diet, infectious and non-infectious other than 
MS diseases, and non-MS-related medications was not recorded as part of this study. Data for 
pregnancies and breastfeeding is not shown as participants who were pregnant or breastfeeding 
were excluded from this study. 
Supplementary Table S2: Total particle:protein ratios. 
Sample EPs/µl protein (µg/ul) EP:protein 
HC 1 (min) 638,009 93.6 6,816 
HC 2 (median) 3,111,339 83.2 37,396 
HC 3 (max) 16,976,719 98.4 172,528 
Relapse 1 (min) 914,385 72.4 12,630 
Relapse 2 (median) 2,430,248 69.2 35,119 
Relapse 3 (max) 5,389,701 90.4 59,621 
RRMS 1 (min) 752,476 89.2 8,436 
RRMS 2 (median) 2,363,787 88.8 26,619 
RRMS 3 (max) 17,287,044 80.8 213,949 
SPMS 1 (min) 818,247 78.0 10,490 
SPMS 2 (median) 2,415,863 78.8 30,658 
SPMS 3 (max) 181,494,963 97.6 1,859,580 
Protein concentrations were measured for the sample with minimum, median and maximum 
total extracellular particle number in each group. EP – extracellular particle; HC – healthy 
control; RRMS – relapsing-remitting Multiple Sclerosis; SPMS – secondary progressive 
Multiple Sclerosis. 
  
Supplementary Figure S1: Full western blots. 
 
 
Supplementary Table S3: Correlations between extracellular particles and bench time. 
EP Spearman’s rho p-value 
CD235a+ 0.381 0.338 
CD41b+ 0.075 0.057 
CD146+ 0.187 0.855 
CD45+ 0.080 0.100 
CD4+ -0.165 0.972 
CD20+ 0.162 0.505 
CD8+ -0.009 0.036 
CD14+ 0.000 0.228 
Correlation for all samples (n= 66). EP – extracellular particle. 
  
Supplementary Figure S2: Percent stained extracellular particles. Pie charts of the total 
EPs (200-1000 nm) detected by flow cytometry and the proportions that stained positive for 
selected CD markers. Values represent median particle number for each CD marker. Data from 
all four groups (HC, RRMS, SPMS, and Relapse, n = 66) was combined. CD – cluster of 
differentiation; EP –extracellular particle; HC – healthy control; RRMS – relapsing-remitting 




Supplementary Table S4: Number of circulating plasma extracellular particles by cell of 
origin and subject group. 
 
HC Relapse RRMS SPMS 
n 27 13 17 9 
 
median IQR median IQR median IQR median IQR 
CD235a positive 
EPs/µl plasma  
40,125 68,040 126,112 93,955 88,674 125,983 67,343 89,976 
CD41b positive 
EPs/µl plasma  
123,854 175,369 31,387 20,732 75,173 274,905 196,814 22,210 
CD146 positive 
EPs/µl plasma  
26,400 28,211 56,923 119,046 40,267 19,977 38,627 41,088 
CD45 positive 
EPs/µl plasma  
24,704 23,363 11,378 14,495 19,229 26,946 35,107 46,784 
CD20 positive 
EPs/µl plasma  
6,261 6,066 5,836 8,742 7,750 6,090 7,205 4,301 
CD4 positive 
EPs/µl plasma 
47,716 74,719 2,282 4,353 51,768 129,340 24,005 51,826 
CD8 positive 
EPs/µl plasma  
8,307 7,504 5,098 14,080 6,127 4,945 3,023 6,857 
CD14 positive 
EPs/µl plasma  
2,965 2,521 4,936 13,861 4,422 6,949 5,061 4,872 
EP – extracellular particle; HC – healthy control; IQR – interquartile range; RRMS – relapsing-
remitting Multiple Sclerosis; SPMS – secondary progressive Multiple Sclerosis. 
 
